Diligence in monitoring the patient and taking the appropriate actions of adjusting BP, administration of anticoagulants, or surgical correction of the stenosis may be necessary. Such scenarios do not refute the notion that an SBP target <120 mm Hg in most adults is bene cial and not associated with increased signi cant adverse events. Clinical events. Within the CKD subgroup, SPRINT reported no signi cant difference in serious adverse events, and in adverse events associated with hypotension, postural hypo- tension, syncope, bradycardia, and injurious falls between the intensive (<120 mm Hg SBP) and standard (<140 mm Hg SBP) BP arms. Among the participants aged $75 years or even $80 years at baseline, of which approximately 44% and 50%, respectively, had an eGFR <60 ml/min per 1.73 m2 , the risk pro le for clinical adverse events with intensive BP lowering was also quite favorable.96,107 There were no differ- ences in serious adverse events and injurious falls between the intensive and standard BP arms. In SPRINT, standing BP was measured at prespeci ed visits.149 Intensive BP lowering reduced, rather than increased, the risk of orthostatic hypo- tension. Further, orthostatic hypotension was not associated with a higher risk of CV disease events, falls, or syncope.93 However, it is reasonable to consider a change in medica- tions or less-intensive therapy if the patient is symptomatic or BP is excessively low (e.g., SBP <100 mm Hg). Electrolyte abnormalities. Within the CKD subgroup, SPRINT reported no signi cant difference in adverse events associated with hyponatremia or hypernatremia between standard and intensive BP arms. However, there were increased risks for hy- pokalemia (HR: 1.87; 95% CI: 1.02 3.43) and hyperkalemia (HR: 1.36; 95% CI: 1.01 1.82), presumablybecause of the greater use of antihypertensive medications in the intensive BP arm. Acute kidney injury. 